🇺🇸 FDA

Intelligence · Clinical Pipeline

Autoimmune & immunology · Phase II

Autoimmune & immunology programs at Phase II — ClinicalTrials.gov pipeline intelligence.

Programs
327

Quick answer

Autoimmune & immunology Phase II programs: NovaPharmaNews indexes 327 matching clinical development programs from ClinicalTrials.gov with sponsor, modality, and NCT cross-links.

Top sponsors

Page 4 of 7

  1. JY231 injection

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Systemic Lupus Erythematosus (SLE)

    phase 2 small molecule active

    1 trial

  2. Jueyin granules

    The First People's Hospital of Lianyungang

    Psoriasis Vulgaris

    phase 2 small molecule active

    1 trial

  3. Jueyin granules

    Universal Integrated

    Plaque Psoriasis

    phase 2 small molecule active

    1 trial

  4. KPL-404

    Kiniksa Pharmaceuticals International, plc

    Arthritis, Rheumatoid

    phase 2 small molecule completed

    1 trial

  5. KYV-101 anti-CD19 CAR-T cell therapy

    Kyverna Therapeutics

    Lupus Nephritis

    phase 2 mab active

    2 trials

  6. KYV101

    Kyverna Therapeutics

    Rheumatoid Arthritis

    phase 2 small molecule active

    1 trial

  7. LEO 90105

    LEO Pharma A/S

    Psoriasis Vulgaris

    phase 2 small molecule completed

    1 trial

  8. LNA043

    Novartis Pharmaceuticals

    Osteoarthritis

    phase 2 small molecule active

    1 trial

  9. LX3305 low dose

    LEXICON PHARMACEUTICALS, INC.

    Rheumatoid Arthritis

    phase 2 small molecule completed

    1 trial

  10. LY3471851

    Nektar Therapeutics UK Limited

    Colitis, Ulcerative

    phase 2 small molecule terminated

    1 trial

  11. LY3471851

    Nektar Therapeutics UK Limited

    Systemic Lupus Erythematosus

    phase 2 small molecule completed

    2 trials

  12. LY3871801

    RIGEL PHARMACEUTICALS INC

    Rheumatoid Arthritis

    phase 2 small molecule completed

    1 trial

  13. LY4268989

    Eli Lilly and Company

    Ulcerative Colitis (UC)

    phase 2 small molecule active

    1 trial

  14. Lanraplenib

    Lakefront Biotherapeutics NV

    Cutaneous Lupus Erythematosus

    phase 2 small molecule completed

    1 trial

  15. Laquinimod

    Teva Pharma GmbH

    Crohn's Disease

    phase 2 small molecule completed

    1 trial

  16. Laquinimod

    Teva Pharma GmbH

    Lupus Arthritis

    phase 2 small molecule completed

    1 trial

  17. Laquinimod

    Teva Pharma GmbH

    Lupus Nephritis

    phase 2 small molecule completed

    1 trial

  18. Leflunomide

    Sanofi Pasteur

    Systemic Lupus Eythematosus (SLE)

    phase 2 small molecule completed

    1 trial

  19. Leukocyte-Poor Platelet Rich Plasma (LP-PRP)

    United Therapeutics Europe Ltd

    Osteoarthritis, Knee

    phase 2 mab active

    1 trial

  20. Losartan

    United Therapeutics Europe Ltd

    Hip Osteoarthritis

    phase 2 small molecule terminated

    1 trial

  21. Lutikizumab, USP/Ph. Eur.ABBV-323, Universal Placebo (Lutikizumab, Ravagalimab)

    AbbVie Deutschland GmbH & Co. KG

    Rheumatoid Arthritis

    phase 2 small molecule active

    1 trial

  22. M5049 low dose

    Merck KGaA, Darmstadt, Germany

    Systemic Lupus Erythematosus

    phase 2 small molecule active

    1 trial

  23. MK-6194

    Merck KGaA, Darmstadt, Germany

    Systemic Lupus Erythematosus

    phase 2 mab terminated

    1 trial

  24. MOL4239

    Moleculin Biotech

    Psoriasis

    phase 2 small molecule completed

    1 trial

  25. MOVIPREP, MaaT033, MOVIPREP Orange, poudre pour solution buvable, Placebo is an inert coated capsule with no microbiota (active substance) inside. It is composed of a mix of coloring agents and partially pre-gelatinized corn starch in Hydroxypropyl methylcellulose capsule.

    Pari Pharma GmbH

    AXIAL SPONDYLOARTHRITIS

    phase 2 small molecule active

    1 trial

  26. MYCOPHENOLIC ACID , PREDNISONE, MYCOPHENOLATE SODIUM, PREDNISONE, MYCOPHENOLATE SODIUM, Placebo 0 mg hard gelatin capsule size 0 and size 2, (placebo to LNP023), METHYLPREDNISOLONE , IPTACOPAN, PREDNISONE, PREDNISONE, PREDNISONE, PREDNISONE, LNP023, Placebo to prednisone

    Novartis Pharmaceuticals

    Lupus Nephritis Class III-IV, +/- V

    phase 2 small molecule active

    1 trial

  27. Maraviroc

    Pfizer

    Arthritis, Rheumatoid

    phase 2 small molecule terminated

    1 trial

  28. Match Placebo to Test Product, SAR441566, SAR441566

    Sanofi-aventis Healthcare Pty Ltd

    Psoriasis

    phase 2 small molecule active

    1 trial

  29. Match placebo to test product, Balinatunfib

    Sanofi-aventis Healthcare Pty Ltd

    Crohn's disease

    phase 2 small molecule active

    1 trial

  30. Match placebo to test product, METHOTREXATE , SAR441566, SAR441566

    Sanofi-aventis Healthcare Pty Ltd

    Rheumatoid arthritis

    phase 2 small molecule active

    1 trial

  31. Matching placebo tablets without active substance, BI 706321, BI 706321, BI 706321, STELARA 130 mg concentrate for solution for infusion, STELARA 90 mg solution for injection in pre-filled pen

    Boehringer Ingelheim

    Crohn`s Disease (CD)

    phase 2 small molecule active

    1 trial

  32. Mesenchymal progenitor cells

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Knee Osteoarthritis

    phase 2 mab completed

    1 trial

  33. Micronized DHACM 40 mg

    United Therapeutics Europe Ltd

    Knee Osteoarthritis

    phase 2 mab terminated

    1 trial

  34. Mirikizumab - Intravenous (IV)

    Eli Lilly and Company

    Colitis, Ulcerative

    phase 2 small molecule active

    1 trial

  35. Mosunetuzumab

    Hoffmann-La Roche

    Systemic Lupus Erythematosus (SLE) With or Without Active Lupus Nephritis (LN)

    phase 2 small molecule active

    1 trial

  36. NANOBODY® Placebo; The placebo is a standard placebo formulation containing common excipients for NANOBODY drug products and is used by Sanofi for NANOBODY clinical studies., SAR442970

    Sanofi-aventis Healthcare Pty Ltd

    Crohn’s disease

    phase 2 small molecule active

    1 trial

  37. NDI-034858

    Takeda

    Psoriatic Arthritis

    phase 2 small molecule completed

    1 trial

  38. NDI-034858 study drug

    Takeda

    Moderate to Severe Plaque Psoriasis

    phase 2 small molecule completed

    1 trial

  39. NKTR-181

    Nektar Therapeutics UK Limited

    Osteoarthritis of the Knee

    phase 2 small molecule completed

    1 trial

  40. NMD670, NMD670, Placebo

    Lacuna Pharma Pty Ltd

    Myasthenia Gravis

    phase 2 small molecule active

    1 trial

  41. Namilumab

    Takeda

    Rheumatoid Arthritis

    phase 2 small molecule completed

    2 trials

  42. Namilumab

    Takeda

    Plaque Psoriasis

    phase 2 small molecule completed

    1 trial

  43. Natrunix

    XBiotech Germany GmbH

    Rheumatoid Arthritis

    phase 2 small molecule completed

    1 trial

  44. Natrunix 400 mg

    XBiotech Germany GmbH

    Rheumatoid Arthritis

    phase 2 mab active

    1 trial

  45. Natrunix with MTX placebo (+folate)

    XBiotech Germany GmbH

    Rheumatoid Arthritis

    phase 2 small molecule active

    1 trial

  46. Not the same excipients as Test, Balinatunfib

    Sanofi-aventis Healthcare Pty Ltd

    Colitis Ulcerative

    phase 2 small molecule active

    1 trial

  47. OD-07656

    Odyssey Therapeutics

    Ulcerative Colitis (UC)

    phase 2 small molecule active

    1 trial

  48. OD-07656, OD-07656, Entyvio 300 mg powder for concentrate for solution for infusion

    Odyssey Therapeutics

    Moderately to Severely Active Ulcerative Colitis

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many autoimmune & immunology Phase II programs exist?

327 programs match both the therapeutic area and stage filters in our published index.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.